Arcutis director sells 38K shares after option exercise
Arcutis Biotherapeutics, Inc. director Terrie Curran reported option exercises and share sales.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Arcutis Biotherapeutics, Inc. director Terrie Curran reported option exercises and share sales. On August 27, 2026, Curran exercised stock options covering 38,200 shares of common stock at exercise prices of $7.51 and $8.63 per share, then sold the same 38,200 shares at a weighted average price of $25.0294 per share, with individual sale prices ranging from $25.00 to $25.1001.
Insider Trade Summary
Exercise and Sale: 38,200 shares ($639K approx. pre-tax spread)
Exercise and Sale
6 txns
Insider
Curran Terrie
Role
Director
Sold
38,200 shs ($956K)
Approx. gross sale proceeds
$956K
Approx. exercise cost
$317K
Approx. pre-tax spread
$639K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F1, F4 | 11,148 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) F3, F4 | 27,052 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 11,148 | $7.51 | $84K |
| Sale | Common Stock F1, F2 | 11,148 | $25.0294 | $279K |
| Exercise | Common Stock F3 | 27,052 | $8.63 | $233K |
| Sale | Common Stock F3, F2 | 27,052 | $25.0294 | $677K |
Holdings After Transaction:
Stock Option (right to buy) — 0 contracts (Direct);
Common Stock — 23,526 shares (Direct)
Footnotes (4)
- F1. The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.
- F2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3. The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service.
- F4. The option is fully vested.
Key Figures
Options Exercised Shares: 38,200 shares
Exercise Price: $7.51 per share
Exercise Price: $8.63 per share
+4 more
7 metrics
Options Exercised Shares
38,200 shares
Total common shares underlying options exercised on August 27, 2026
Exercise Price
$7.51 per share
Exercise price for 11,148-share option exercised on August 27, 2026
Exercise Price
$8.63 per share
Exercise price for 27,052-share option exercised on August 27, 2026
Shares Sold
38,200 shares
Total common shares sold on August 27, 2026
Weighted Average Sale Price
$25.0294 per share
Weighted average sale price for shares sold within a $25.00–$25.1001 range
Option Expiration Date
May 31, 2033
Expiration date of the 11,148-share option that was exercised
Option Expiration Date
June 14, 2034
Expiration date of the 27,052-share option that was exercised
Key Terms
Stock Option (right to buy), weighted average sale price, non-employee director, fully vested, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
weighted average sale price financial
"The price reported in Column 4 is a weighted average sale price."
non-employee director financial
"subject to the non-employee director's continuous service."
fully vested financial
"The option is fully vested."
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did ARQT director Terrie Curran report on August 27, 2026?
Terrie Curran exercised stock options for 38,200 ARQT shares and sold the same 38,200 shares of common stock on August 27, 2026, according to the Form 4.
At what prices were Terrie Curran’s ARQT options exercised?
Terrie Curran exercised stock options to acquire 11,148 shares at an exercise price of $7.51 per share and 27,052 shares at an exercise price of $8.63 per share.
Were the stock options in the ARQT Form 4 fully vested before exercise?
Yes. The Form 4 footnotes state that the options exercised by Terrie Curran were fully vested on the exercise date, having vested 100% on the first anniversaries of May 31, 2023 and June 14, 2024, subject to continuous service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
